What your doctor is reading on Medscape.com:
APRIL 13, 2020 -- Patients with inflammatory bowel disease (IBD) who develop COVID-19 should stop taking thiopurines, methotrexate, tofacitinib, and biological therapies during the viral illness, according to a clinical practice update from the American Gastroenterological Association (AGA).
"While the COVID-19 pandemic is a global health emergency, patients with IBD have particular concerns for their risk for infection and management of their medical therapies. This clinical practice update incorporates the emerging understanding of COVID-19 and summarizes available guidance for patients with IBD and the providers who take care of them," the authors write.
David T. Rubin, MD, University of Chicago Medicine Inflammatory Bowel Disease Center, and colleagues' recommendations were published online April 10 in an expert commentary in Gastroenterology.
Rubin and another author report a variety of financial relationships with pharmaceutical companies.
Patients with IBD are asking whether they are at increased risk for COVID-19, Rubin told Medscape Medical News. "Because they are often on immune-modifying therapy for their inflammatory bowel disease, they worry that they are in the population of folks who are immune compromised.
"In fact, immune suppression is not [the] goal of our management of IBD, it is the immune regulation of an overactive immune response. In some ways, the inflammatory reaction of COVD-19 that results in symptoms and respiratory failure are the same thing — an overactive immune response," he explained.
Clinical Picture May Vary for Patients With IBD and COVID-19
Drugs and biologics that are withheld during viral infection can be resumed once the patient's symptoms have resolved or when follow-up viral testing results are negative or serologic testing shows the patient is in the "convalescent stage of illness," the authors write.
For those hospitalized with severe COVID-19 and at risk of doing poorly, treatment of the IBD will "likely take a back seat" to COVID-19 treatment, but clinicians should consider the coexisting IBD when deciding on therapies for COVID-19 when possible. "It is of interest that clearance of [cytomegalovirus] is enhanced when IBD therapy is added to ganciclovir and that thiopurines and cyclosporine may have anti-coronavirus properties," the authors observe.
For patients who are hospitalized for IBD and who have "milder or incidentally identified COVID-19," the emphasis should be on the acute IBD and on giving standard IBD care.
Patients with IBD who are known to have SARS-CoV-2 infection but who are not ill with COVID-19 should stop taking thiopurines, methotrexate, and tofacitinib. Biological therapies should be withheld for 2 weeks, and the patient should be monitored for COVID-19 symptoms.
Patients With IBD Who Are Not Infected Should Continue IBD Treatment
Those with IBD who are not infected with SARS-CoV-2 should continue with their IBD therapies and with their infusion regimen at "appropriate infusion centers," the authors write.
The goal for these individuals is to sustain symptomatic or clinical remission and "objectively confirmed inflammation control," as evidenced by "endoscopic improvement and normalized laboratory values."
Although some patients may be reluctant to visit infusion centers for fear of exposure to infected individuals, the authors caution that it could be much riskier for a nurse to visit patients in their homes and possibly expose others in the household.
Patients with IBD are worried about having to stop their IBD medications if they get COVID-19, "because maintenance therapies are there to keep their IBD in remission," Rubin told Medscape Medical News.
"The longer a patient is off their therapy for a chronic condition like IBD, the more likely they are to suffer from a relapse of the disease. We reassure them that in most cases, COVID-19 lasts a few weeks and after they have improved, can restart their medications safely."
Role of Anticytokine-Based Treatments and Antivirals for COVID-19 Is Unclear
"It should be known that anti-cytokine-based treatments are being studied for COVID-19 therapy, and it is possible that we will learn that, for example, continuing anti-TNF [tumor necrosis factor] therapies might reduce progression to acute respiratory distress syndrome and multi-organ system failure," the authors explain. "However, in the absence of those data, guidance is currently based on deciding whether to hold or to continue specific IBD therapies.
"Of additional interest are the anti-viral therapies and other anti-cytokine therapies that are being studied for COVID-19. Choosing therapies that may have secondary benefit in IBD (or at least do not induce bowel inflammation) would be appropriate to consider."
When considering treatments for COVID-19 and whether to increase IBD treatment, clinicians and patients should weigh the risks against the benefits.
Social Distancing Works for Patients With IBD
Evidence from the Wuhan IBD center in China suggests that strict social distancing for patients with IBD works, Rubin said.
Gastroenterologists at Wuhan University instituted a number of measures to protect patients with IBD from COVID-19 nearly 3 weeks before the general shutdown in Wuhan. These included distributing educational information and instructions to patients, updating them as needed, and recording patient information, such as infection risks and actions taken. None of the 318 patients with IBD had been diagnosed with the infection at the end of February.
Individuals with IBD should observe strict social distancing, work from their home, practice careful hand hygiene, and stay away from individuals known to be infected, Rubin and colleagues recommend.
Patients With IBD Who Experience Relapse Need Careful Evaluation
Rubin urges clinicians to "carefully evaluate their IBD patients who have a relapse both because it may be digestive symptoms from COVID-19 instead, but also because much more likely it will be the usual causes — other infections, loss of response to therapy or due to patients who stopped their therapy on their own. A thoughtful clinical approach to these patients is critically important so that our patients can be kept safe and get the treatments that they need."
He added, "We are learning more every day about COVID-19 and about new options for testing, screening, and outcomes of our IBD patients who get infected. Patients should check with their doctors if they have concerns or questions, and both patients and clinicians should stay tuned as more information becomes available. The IBD community of experts and care providers are all working together."
A decision support tool and quick reference chart for social sharing are available for download on the AGA website, and clinicians are asked to submit cases involving patients who have both IBD and confirmed COVID-19 to the SECURE-IBD registry.
The AGA Institute Clinical Practice Updates Committee and the AGA Governing Board commissioned and approved this expert commentary. Rubin and Cohen report a variety of financial relationships with pharmaceutical companies and organizations, including AbbVie, Abgenomics, Allergan Inc, BMS/Celgene, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp-Syneos, Dizal Pharmaceuticals, Eli Lilly, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Hollister, Ichnos Sciences SA, GlaxoSmithKline Services, Janssen Pharmaceuticals, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Prometheus Laboratories, Receptos, RedHill Biopharma, Reistone, Sanofi-Aventis, Schwaz Pharma, Seres Therapeutics, Shire, Takeda, Techlab Inc, UCB Pharma, and the Crohn's & Colitis Foundation. Cohen's spouse is on the board of directors at Aerpio Therapeutics, Novus Therapeutics, and NantKwest. The remaining authors have disclosed no relevant financial relationships.